Solid TumorVULNERABILITENCT01415258
Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre
An observational study of Solid Tumor, run by Centre Oscar Lambret at 1 site in France.
Trial summary
The objective of this study is to uncover the prevalence of vulnerability among patients aged ≥ 70 coming to the medical oncology division of the Oscar Lambret Centre, according to the short screening test Vulnerable Elders Survey 13 (VES-13). Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Solid Tumor
- How many people
- 209 participants
- Where
- 1 siteFrance
- Study dates
- Mar 2011to Apr 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: This study concerns elderly patients (≥70 years) with solid tumors
Who may be able to join
- patient aged ≥ 70
- coming for a first visit, whatever the purpose and the disease stage
Who cannot join
- neglect or refusal to answer to the VES-13 test
Trial locations and contacts
1 site in 1 country.
About this study
The objective of this study is to uncover the prevalence of vulnerability among patients aged ≥ 70 coming to the medical oncology division of the Oscar Lambret Centre, according to the short screening test Vulnerable Elders Survey 13 (VES-13).
The objective is to better understand the value of routine screening of patients before the consultation, it was proposed as a secondary objective of this study to assess the correlation between the identification of the vulnerability in the screening test VES-13 and the identification made by the clinician during the consultation. The correlation between VES-13 and opinion of the clinician for three categories of patients (self - intermediate - fragile) will also be studied.
- Conditions
- Solid Tumor
- Keywords
- cancer, vulnerability, frail
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the Vulnerable Elders Survey score (VES-13)
A patient is identified vulnerable if the score is ≥ 3
Measured: Within 3 months after recruitment
Secondary outcomes (2)
To assess the correlation between the VES-13 score and the vulnerability judged by a clinical expert
A patient will be identified as vulnerable if he/she belongs to the "intermediate" or "frail" category. The Kappa coefficient of agreement will be used to correlate the VES-13 score and clinical observations.
Measured: Within 3 months after recruitment
To measure the muscle strength using the grip strength test
Hand Dynamometer Range values : 0-90
Measured: Within 3 months after recruitment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2011 (estimated)
- Study startMar 2011
- Primary completionAug 2011
- Study completionApr 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 209 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Oscar Lambret
- Sponsor type
- University, hospital or other
- Collaborators
- Hôpital Gériatrique Les Bateliers, CHRU Lille
- Responsible party
- Sponsor
- Investigators
- Véronique SERVENT, MD, Principal investigator, Oscar Lambret Anti-Cancer Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01415258
- Sponsor's protocol ID
- VULNERABILITE-1103
- Acronym
- VULNERABILITE
- Status last verified
- Mar 2026
- First submitted
- 10 Aug 2011
- Last updated
- 16 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre
- ClinicalTrials.gov ID
- NCT01415258
- Acronym / sponsor ID
- VULNERABILITE / VULNERABILITE-1103
- Conditions
- Solid Tumor
- Keywords
- cancer, vulnerability, frail
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 209 participants (actual)
- Lead sponsor
- Centre Oscar LambretUniversity, hospital or other
- Collaborators
- Hôpital Gériatrique Les Bateliers, CHRU Lille
- Study start
- Mar 2011 (actual)
- Primary completion
- Aug 2011 (actual)
- Study completion
- Apr 2012 (actual)
- First posted
- 11 Aug 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to uncover the prevalence of vulnerability among patients aged ≥ 70 coming to the medical oncology division of the Oscar Lambret Centre, according to the short screening test Vulnerable Elders Survey 13 (VES-13).
The objective is to better understand the value of routine screening of patients before the consultation, it was proposed as a secondary objective of this study to assess the correlation between the identification of the vulnerability in the screening test VES-13 and the identification made by the clinician during the consultation. The correlation between VES-13 and opinion of the clinician for three categories of patients (self - intermediate - fragile) will also be studied.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- This study concerns elderly patients (≥70 years) with solid tumors
Key inclusion criteria (2 listed)
- patient aged ≥ 70
- coming for a first visit, whatever the purpose and the disease stage
Key exclusion criteria (1 listed)
- neglect or refusal to answer to the VES-13 test
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To assess the Vulnerable Elders Survey score (VES-13)
Time frame: Within 3 months after recruitment
A patient is identified vulnerable if the score is ≥ 3
2 secondary outcomes
To assess the correlation between the VES-13 score and the vulnerability judged by a clinical expert
Time frame: Within 3 months after recruitment
To measure the muscle strength using the grip strength test
Time frame: Within 3 months after recruitment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2026.
Related trials for Solid Tumor
Not yet recruitingPhase 2
Saruparib in HRDsig+ Solid Tumors
Malignant Neoplastic Disease (Disorder)
Not yet recruitingPhase 1
A Study of Mesothelin-Targeted CAR-Mix Cells in Patients With Advanced Solid Tumors
Mesothelin-Positive Advanced Solid Tumors With Peritoneal Metastasis
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingPhase 1/2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Colorectal Cancer
RecruitingPhase 2
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Véronique SERVENT, MD principal investigator
Oscar Lambret Anti-Cancer Centre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Solid Tumor, run by Centre Oscar Lambret at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the Vulnerable Elders Survey score (VES-13) (time frame: Within 3 months after recruitment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.